Insulet (PODD) Misses Q2 EPS by 1c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Use the pullback to buy pullback in this MedTech stock: JPMorgan
August 12, 2024 4:00 PM EDTJPMorgan analysts urged investors to capitalize on the recent pullback in one medtech company's shares.
The firm said in a note to clients Monday that Insulet's (NASDAQ: PODD) strong fundamentals and positive outlook mean they are buyers.
The analysts express frustration over the stock's decline following earnings last week, emphasizing that the drop is not reflective of the company's... More
Insulet Corporation (PODD) PT Lowered to $250 at BTIG
August 9, 2024 4:58 AM EDTBTIG analyst Marie Thibault lowered the price target on Insulet Corporation (NASDAQ: PODD) to $250.00 (from $270.00) while maintaining a Buy rating.
The analyst comments "Following its preannouncement in late July, Insulet reported Q2 revenue of $488.5M (+23% y/y rep and cc), a ~$27M beat on consensus at the time of the preannouncement. The beat came from all business segments and was attributed to strong O5 demand that drove sequential increases in new customer starts both in the... More
